Thomas Fuchs | search
Click here to view Thomas Fuchs news from 60+ newspapers.
Bookmark or Share- Lilly appoints Thomas J. Fuchs as the company’s first chief AI officerINDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, effective Oct. 21, 2024. In this role, Fuchs will provide vision, strategic direction and overall leadership of AI initiatives across Lilly, including drug discovery, clinical trials ...
- Thomas Fuchs - Icahn School of Medicine at Mount SinaiThomas Fuchs. DrSc. Hasso Plattner Institute for Digital Health at Mount Sinai. Graduate School of Biomedical Sciences. Artificial Intelligence and Human Health. Icahn School of Medicine at Mount Sinai. h-index. 4681. Citations.
- Lilly names Mount Sinai scientist as first chief AI officerEli Lilly is taking artificial intelligence’s potential seriously, announcing Tuesday the appointment of the Indianapolis drugmaker’s first chief AI officer. Thomas Fuchs, until now the dean and department chair for AI and human health at Mount Sinai, will start in the role on Oct. 21, Lilly said.
- Thomas J Fuchs | Mount Sinai - New YorkThomas J. Fuchs, Dr.sc., is a scientist in the groundbreaking field of Computational Pathology, focused on the use of artificial intelligence to analyze images of tissue samples to identify disease, recommend treatment and predict outcome. In October 2020, he has been appointed Co-Director of the Hasso Plattner Institute for Digital Health at ...
- Thomas J. Fuchs - Google Scholar2021. Articles 1–20. Icahn School of Medicine at Mount Sinai - Cited by 10,115 - Machine Learning - Computational Pathology - Digital Pathology - Deep Learning - Artificial Intelligence.
More
